Interaction of calcium channel blockers and excitatory amino acid antagonists with conventional antiepileptic drugs

CNS Drug Reviews

Volumn 2, Issue 4, 1996, Pages 452-467

  Czuczwar, S J ^a   Kleinrok, Z ^a   Turski, W A ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Calcium channel blockers; Epilepsy; Excitatory amino acid antagonists; Seizures

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CGP 39847; CLONAZEPAM; DILTIAZEM; DIZOCILPINE; ETHOSUXIMIDE; FLUNARIZINE; IFENPRODIL; KAINIC ACID RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIFEDIPINE; NIMODIPINE; PHENOBARBITAL; PHENYTOIN; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BRAIN PROTECTION; CLINICAL TRIAL; CONVULSION; DRUG POTENTIATION; EPILEPSY; HUMAN; NONHUMAN;

EID: 0030431596     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00311.x     Document Type: Article

References (90)

1. Bacia T. Remission of seizures after therapy with calcium antagonist (nifedipine) in a patient with severe generalized epilepsy. Pol Tyg Lek 1994;49:122-123.
2. Bebin M, Bleck TP. New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam, and stiripentol. Drugs 1994;48:153-171.
3. Ben-Ari Y, Lagowska J, Tremblay E, Le Gal LaSalle G. A new model of focal status epilepticus: Intraamygdaloid application of kainic acid elicits repetitive secondarily generalized convulsive seizures. Brain Res 1979;163:176-179.
4. Binnie CD. Potential antiepileptic drugs. Flunarizine and other calcium entry blockers. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic Drugs, Third Edition. New York: Raven Press, 1989:971-982.
5. Binnie CD, de Beukelaar F, Meijer JW, et al. Open dose-ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1985;26:424-428.
6. Boissier J-R, Tardy J, Diverres J-C. Une nouvelle methode simple pour explorer l'action 'tranquilisante': Le test de la cheminee. Med Exp 1960;3:81-84.
7. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ. The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 1995;281:319-325.
8. Brodic MJ, Mcphee GJA. Carbamazepinc neurotoxicity precipitated by diltiazem. Br Med J 1986;292:1170-1171.
9. Croucher MJ, Collins JF, Meldrum BS. Anticonvulsant action of excitatory amino acid antagonists. Science 1982;216:899-901.
10. Czechowska G, Dziki M, Pietrasiewicz T, Kleinrok Z, Turski WA, Czuczwar SJ. Competitive antagonists of NMDA receptors, CGP 37849 and CGP39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice. Eur J Pharmacol 1993;232:59-64.
11. Czuczwar SJ, Meldrum BS. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur J Pharmacol 1982;83:335-338.
12. Czuczwar SJ, Kleinrok Z. Modulation of the protective efficacy of common antiepileptic drugs by xanthine derivatives: Implications for the clinical use of xanthines in epileptic patients. Pharmacol Res 1990;22:661-665.
13. Czuczwar SJ, Borowicz KK, Kleinrok Z, Tutka P, Żarnowski T, Turski WA. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. Eur J Pharmacol 1995;281:327-333.
14. Czuczwar SJ, Cavalheiro EA, Turski L, Turski WA, Kleinrok Z. Phosphonic analogues of excitatory amino acids raise the threshold for maximal electroconvulsions in mice. Neurosci Res 1985;3:86-90.
15. Czuczwar SJ, Chodkowska A, Kleinrok Z, Małek U, Jagiello-Wójtowicz E. Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur J Pharmacol 1990;176:75-83.
16. Czuczwar SJ, Frey H-H, Löscher W. Antagonism of N-methyl-D,L-aspartic acid-induced seizures by antiepileptic drugs and other agents. Eur J Pharmacol 1985;108:273-280.
17. Czuczwar SJ, Gasior M, Janusz W, Kleinrok Z. Influence of flunarizine, nicardipine, and nimodipine on the anticonvulsant activity of different antiepileptic drugs in mice. Neuropharmacology 1992;31:1179-1183.
18. 2+ channel agonist, BAY K-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists. Eur J Pharmacol 1994;264:103-106.
19. Czuczwar SJ, Ikonomidou C, Kleinrok Z, Turski L, Turski W. Effect of aminophylline on the protective action of common antiepileptic drugs against electroconvulsions in mice. Epilepsia 1986;27:204-208.
20. Czuczwar SJ, Małek U, Kleinrok Z. Influence of calcium channel inhibitors upon the anticonvulsant efficacy of common antiepileptics against pentylenetetrazol-induced convulsions in mice. Neuropharmacology 1990;29:943-948.
21. Czuczwar SJ, Turski L, Schwarz M, Turski WA, Kleinrok Z. Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydantoin in mice. Eur J Pharmacol 1984;100:357-362.
22. Danysz W, Essman U, Bresink I, Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994;48:111-118.
23. Deckert J, Bereznai B, Hennemann A, et al. Nimodipine inhibits [3H]nitrobenzylthioinosine binding to the adenosine transporter in human brain. Eur J Pharmacol 1993;238:131-133.
24. De Falco FA, Bartiromo U, Majello L, Di Geronimo D, Mundo P. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992;33:343-345.
25. De Sarro GB, Meldrum BS, Nistico G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 1988;93:247-256.
26. Desmedt LKC, Niemegeers CJE, Janssen PAJ. Anticonvulsant properties of cinnarizine and flunarizine in mice. Arzneim Forsch 1976,25:1408-1413.
27. Dichter MA. Cellular mechanisms of epilepsy and potential new treatment strategies. Epilepsia (Suppl 5) 1992;33:3-12.
28. Dolin SJ, Hunter AB, Halsey MJ, Little HJ. Anticonvulsant profile of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine. Eur J Pharmacol 1988;152:19-27.
29. ®). Epileptologia 1994;2:242.
30. Fischer R. S. Foreward. Epilepsia (Suppl 5) 1992;33:1-2.
31. Fischer W. Einfluss von Flunarizin auf die antikonvulsive Wirksamkeit von Phenobarbital beim maximalen Elektrokrampf der Maus. Pharmazie 1987;42:743-744.
32. Fischer W. Pharmakologische Modulation der antikonvulsiven Wirksamkeit von Calcium-Valproat beim maximalen Elektrokrampf der Maus. Pharmazie 1989;44:356-357.
33. Flaim SF, Zelis R. Diltiazem: Systemic coronary vasodilator without negative ionotropic effects on conscious rats. Fed Proc 1980;39:709.
34. Flaim SF, Kanda K. Comparative pharmacology of calcium blockers based on studies of cardiac output distribution. In: Flaim SF, Zelis R, eds. Calcium Blockers: Mechanisms of Action and Clinical Applications. Baltimore: Urban & Schwarzenberg 1982:179-192.
35. Gasior M, Kaminski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine, and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm 1996;103:819-831.
36. Gasior M, Kleinrok Z, Czuczwar SJ. Influence of BAY K-8644, a calcium channel agonist, on the anticonvulsant activity of conventional antiepileptics against electroconvulsions in mice. Neuropharmacology 1995;34:433-138.
37. Gordon R, Gels M, Wichmann J, Diamantis W, Sofia RD. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia 1993;34:367-371.
38. Hamann SR, Todd GD, McAllister RG. The pharmacology of verapamil. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology 1983;27:1-8.
39. Harden CL. New antiepileptic drugs. Neurology 1994;44:787-795.
40. Heinemann U, Pumain R. Effects of tetrodotoxin on changes in extracellular free calcium induced by re-petitive electrical stimulation and iontophoretic application of excitatory amino acids in the sensorimotor cortex of rats. Neurosci Lett 1981;21:87-91.
41. + potential. Am Neurol 1981;10:11-17.
42. Huxtable RJ, Laird H, Lippincott SE, Wolson P. Epilepsy and the concentration of plasma amino acids in liumans. Neurochem Int 1983;5:125-135.
43. Jagiełło-Wójtowicz E, Czuczwar SJ, Chodkowska E, Szponar J, Kleinrok Z. Influence of calcium channel blockers on pentylenetetrazol- and electroshock-induced convulsions in mice. Pol J Pharmacol Pharm 1991;43:95-101.
44. Kalviainen R, Aikia M, Riekkinen PJ. Gamma-vinyl GABA (vigabatrin) monotherapy: efficacy, safely, and cognitive profile during two-year follow-up. Epilepsia (Suppl 3) 1992;33:118.
45. Kleinrok Z, Czuczwar SJ, Turski L. Prevention of kainic acid-induced seizure-like activity by antiepileptic drugs. Pol J Pharmacol Pharm 1980;32:261-264.
46. Larkin JG, Besag FM, Cox A, Williams J, Brodie MJ. Nifedipine for epilepsy? A double-blind, placebo-controlled trial. Epilepsia 1992;33:346-352.
47. Larkin JG, McKee PJW, Blacklaw J, Thompson GG, Morgan IC, Brodie MJ. Nimodipine in refractory epilepsy: A placebo-controlled, add-on study. Epilepsy Res 1991;9:71-77.
48. Larkin JG, Thompson GG, Scobie G, Forrest G, Drennan JE, Brodie MJ. Dihydropyridine calcium antagonists in mice: Blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia 1992;33:760-769.
49. Löscher W, Hönack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther 1991;256:432-440.
50. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:145-181.
51. Löscher W, Jäckel R, Czuczwar SJ. Is amygdala kindling in rats a model for drug-resistant partial epilepsy? Exp Neurol 1986;93:211-226.
52. Löscher W, Nolting B, Hönack D. Evaluation of CPP, a selective NMDA antagonist in various models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur J Pharmacol 1988;152:9-17.
53. Löscher W, Rundfeldt C, Hönack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur J Neurosci 1993;5:1545-1590.
54. Macphee GJA, Thompson GG, Gordon T, McInnes M, Brodie MJ. Verapamil potentiates carbamazepine neurotoxicity: A clinically important inhibitory interaction. Lancet 1986;700-703.
55. Meldrum BS. Amino acid neurotransmitters and new approaches to anticonvulsant drug action. Epilepsia 1984;25:S140-S149.
56. Merritt HU, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 1937;39:1003-1015.
57. Meyer FB, Cascino GD, Whisnant JP, et al. Nimodipine as an add-on therapy for intractable epilepsy. Mayo Clin Proc 1995;70:623-627.
58. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system. Ann Rev Pharmacol Toxicol 1989;29:365-402.
59. Nakane Y, Seino M, Yagi A, Kaji S, Yamauchi T. Effects of flunarizine therapy on intractable epilepsy. Arzneim Forsch 1989;39:793-798.
60. Overweg J, Binnie CD, Meijer JWA, et al. Double-blind, placebo-controlled trial of flunarizine as addon therapy in epilepsy. Epilepsia 1984;25:217-222.
61. Palmer GC, Stagnitto ML, Ray RK, Knowles MA, Harvey R, Garske GE. Anticonvulsant properties of calcium channel blockers in mice: N-methyl-D,L-aspartate- and Bay K 8644-induced convulsions are potently blocked by the dihydropyridines. Epilepsia 1993;34:372-380.
62. Parada J, Czuczwar SJ, Turski WA. NBQX does not affect learning and memory tasks in mice: A comparison with D-CPP-ene and ifenprodil. Cog Brain Res 1992;1:67-71.
63. Pietrasiewicz T, Czechowska G, Dziki M, Turski WA, Kleinrok Z, Czuczwar SJ. Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. Eur J Pharmacol 1993;250:1-7.
64. Porter RJ. New antiepileptic agents: Strategies for drug development. Lancet 1990;336:423-424.
65. Pumain R, Kurcewicz I, Louvel J. Fast extracellular calcium transients: involvement in epileptic processes. Science 1984;222:177-179.
66. Sander JWAS. Some aspects of prognosis in the epilepsies: A review. Epilepsia 1993;34:1007-1016.
67. Schmutz M, Portet C, Jeker A, et al. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent orally active anticonvulsants in rodents. Naunyn-Schmiedeberg's Arch Pharmacol 1990;342:61-66.
68. Shelton RC, Grebb JA, Freed WJ. Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist BAY K-8644. Brain Res 1987;402:399-402.
69. Smith SE, Durmuller N, Meldrum BS. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX, are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1991;201:179-183.
70. Speckmann EJ, Stroub H, Köhling R. Contribution of calcium ions to the generation of epileptic activity and antiepileptic calcium antagonism. Neuropsychobiology 1993;27:122-126.
71. Starrevald E, De Beukelaar F, Wilson AF, McLean DR, Findlay HP. Double-blind, cross-over, placebo-controlled study of flunarizine in patients with therapy resistant epilepsy. Can J Neurol Sci 1989;16:187-190.
72. Steppuhn KG, Turski L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther 1993;265:1063-1070.
73. Stone WE, Javid MJ. Effects of anticonvulsants and other agents on seizures induced by intracerebral L-glutamate. Brain Res 1983;264:165-167.
74. Sveinbjornsdottir S, Sander JWAS, Upton D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993;16:165-174.
75. Tarnawa I, Engberg I, Flatman JA. GYKI 52466, an inhibitor of spinal reflexes, is a potent quisqualate antagonist. In: Lubec G, Rosenthal GA, eds. Amino Acids: Chemistry, Biology and Medicine. Leiden: Escom, 1990:538-546.
76. Troupin AS, Mendius JR, Cheng F, Risinger MW. MK-801. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs. London, Paris: John Libbey, 1986:191-201.
77. Turski WA, Urbanska E, Dziki M, Parada-Turska J, Ikonomidou C. Excitatory amino acid antagonists protect mice against seizures induced by bicuculline. Brain Res 1990;514:131-134.
78. Turski L, Niemann W, Stephens DN. Differential effects of antiepileptic drugs and carbolines on seizures induced by excitatory amino acids. Neuroscience 1990;39:799-807.
79. Turski L, Jacobsen P, Honoré T, Stephens DN. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline. J Pharmacol Exp Ther 1992;260:742-747.
80. Urbańska E, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA. Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol 1991;200:277-282.
81. Venault P, Chapouthier G, de Carvalho LP, et al. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 1986;321:864-866.
82. Wamil AW, McLean MJ. Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons. J Pharmacol Exp Ther 1993;267:218-227.
83. Watkins JC, Krogsgaard-Larsen P, Honoré T. Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 1990;11:25-33.
84. White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995;20:41-48.
85. Yarbrough GG, McGuffin-Clineschmidt JC. In vivo behavioral assessment of central nervous system purigenic receptors. Eur J Pharmacol 1981;76:137-144.
86. Zeise ML, Kasparow S, Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991;544:345-348.
87. Zorumski CF, Thio LL. Properties of vertebrate glutamate receptors: Calcium mobilization and desensitization. Prog Neurobiol 1992;39:295-336.
88. Żarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinox-aline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993;32:895-900.
89. Żarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ. The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshock-induced seizures in mice. J Neural Transm 1994;97:1-12.
90. Żarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ. The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. Neuropharmacology 1994;33:619-624.